Results 71 to 80 of about 231,868 (346)

“Online survey of COVID-19 immunization and infection in patients with systemic juvenile idiopathic arthritis and adult-onset still’s disease.”

open access: yesPediatric Rheumatology Online Journal, 2023
Background Patients with systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD) have been under-represented in studies about safety of the COVID-19 immunization. We aimed to inquire about the safety and tolerability of COVID-
Mariana Correia Marques   +7 more
doaj   +1 more source

A retrospective study on 195 horses with contaminated and infected synovial cavities [PDF]

open access: yes, 2009
This study analyzes the clinical aspects of contaminated and infected synovial cavities in horses and evaluates their prognosis after treatment. The medical records of 195 affected horses referred between June 1999 and July 2004 were reviewed. Twenty-six
Dewulf, Jeroen   +5 more
core   +1 more source

Macrophage Activation Syndrome as Onset of Systemic Lupus Erythematosus: A Case Report and a Review of the Literature [PDF]

open access: yes, 2015
Macrophage activation syndrome (MAS) is a potentially fatal condition. It is a rare complication of several autoimmune disorders, including systemic lupus erythematosus (SLE) and systemic juvenile idiopathic arthritis (sJIA).
Didona, Dario   +4 more
core   +4 more sources

Diffusion‐Weighted Imaging for the Evaluation of the Sacroiliac Joint in Pediatric Patients

open access: yesArthritis Care &Research, EarlyView.
Objective Maturational signal in the sacroiliac joint (SIJ) of skeletally immature youth is often misinterpreted as inflammation. Diagnostic tools that improve specificity are greatly needed. Apparent diffusion coefficient (ADC) values from diffusion‐weighted imaging (DWI), when used with standard imaging, may enhance diagnostic accuracy.
Michael L. Francavilla   +6 more
wiley   +1 more source

Reactive or infectious arthritis [PDF]

open access: yesAnnals of the Rheumatic Diseases, 1999
A role for bacterial infection in the aetiology of inflammatory arthritis has been suspected for many years. Yet over that relatively long period of time only a few acute or chronic arthritides have been unequivocally linked to an infectious agent; these include septic arthritis, rheumatic fever, and, more recently, Lyme arthritis.
J G, Kuipers, L, Köhler, H, Zeidler
openaire   +2 more sources

Clinical Conditions Associated With a High Antinuclear Antibody Titer in Individuals Without Autoimmune Disease

open access: yesArthritis Care &Research, EarlyView.
Objective Antinuclear antibodies (ANAs) are present at high titers in 2% of the general population, but their clinical significance in individuals without an autoimmune (AI) disease is not known. We tested the hypothesis that the presence of a high ANA titer in non‐AI conditions is associated with disease.
Matthew Chung   +7 more
wiley   +1 more source

Parvovirus B19 infection and its role in rheumatology

open access: yesСовременная ревматология
The article summarizes modern data on the parvovirus (PV) B19 infection and associated conditions in rheumatological practice. Special attention is paid to the features of the structure and replication of the virus in infected cells of macroorganism ...
G. I. Gridneva   +3 more
doaj   +1 more source

Human adenoviral (HAdV) chronic arthritis expands the infectious spectrum of primary agammaglobulinemia [PDF]

open access: gold, 2022
Grégoire Martin de Frémont   +13 more
openalex   +1 more source

Sarilumab in Polyarticular‐Course Juvenile Idiopathic Arthritis: Dose‐Finding and One‐Year Analysis of a Phase 2b, Open‐Label, Multicenter Study

open access: yesArthritis Care &Research, Accepted Article.
Objective This study assessed sarilumab in treating patients with polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods This phase 2b, open‐label study (NCT02776735) consisted of three sequential parts (each with a core‐treatment and extension‐phase). During part 1, three doses were assessed in two weight groups (Group A/B: ≥30–60 kg/≥10–<
Fabrizio De Benedetti   +19 more
wiley   +1 more source

Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study

open access: yesArthritis Research & Therapy, 2023
Background Upadacitinib, a Janus kinase inhibitor, has demonstrated efficacy and an acceptable safety profile in patients with ankylosing spondylitis (AS) in the phase III SELECT-AXIS programs. We report the 1-year efficacy and safety in patients with AS
Xenofon Baraliakos   +10 more
doaj   +1 more source

Home - About - Disclaimer - Privacy